Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Takeout premiums hold up, but that’s not the whole story
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.
The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Digging into biopharma’s big buyout areas
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Biding your time buying is becoming costly
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
